These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30790690)

  • 1. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
    Droppa M; Vaduganathan M; Venkateswaran RV; Singh A; Szumita PM; Roberts RJ; Qamar A; Hack L; Rath D; Gawaz M; Fuernau G; de Waha-Thiele S; Desch S; Schneider S; Ouarrak T; Jaffer FA; Zeymer U; Thiele H; Bhatt DL; Geisler T
    Resuscitation; 2019 Apr; 137():205-212. PubMed ID: 30790690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
    Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of data on cangrelor.
    Qamar A; Bhatt DL
    Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
    Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
    JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periprocedural platelet inhibition with cangrelor in P2Y
    Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
    Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry.
    Rymer J; Pichan C; Page C; Alhanti B; Bhatt DL; Kochar A; Angiolillo DJ; Diaz M; Wimmer NJ; Waksman R; Ang L; Bach R; Jenkins R; El-Sabae H; Brothers L; Ohman EM; Jones WS; Washam JB; Wang TY; Narcisse D; Basir MB
    J Card Fail; 2024 Oct; 30(10):1233-1240. PubMed ID: 39389732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Yerasi C; Case BC; Chezar-Azerrad C; Forrestal BJ; Medranda GA; Shea C; Zhang C; Ben-Dor I; Satler LF; Bernardo NL; Hashim H; Garcia-Garcia HM; Waksman R
    Am Heart J; 2021 Aug; 238():59-65. PubMed ID: 33961829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention.
    Hideo-Kajita A; Rogers T; Buchanan K; Iantorno M; Gajanana D; Ozaki Y; Dan K; Kolm P; Brathwaite E; Beyene S; Melaku G; Meirovich Y; Dheendsa A; Garcia-Garcia HM; Torguson R; Waksman R
    Am J Cardiol; 2019 Apr; 123(8):1228-1238. PubMed ID: 30738570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Expert Opin Drug Saf; 2016; 15(2):275-85. PubMed ID: 26680584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and/or After Cardiopulmonary Resuscitation.
    Kanic V; Vollrath M; Penko M; Markota A; Kompara G; Kanic Z
    Heart Lung Circ; 2018 Jan; 27(1):73-78. PubMed ID: 28377230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and safety of cangrelor in patients with suboptimal P2Y
    Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
    BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the Use of Cangrelor in the Real World.
    Qamar A; Bhatt DL
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):5-16. PubMed ID: 27677505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
    Capodanno D; Milluzzo RP; Angiolillo DJ
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719893274. PubMed ID: 31823688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cangrelor for treatment during percutaneous coronary intervention.
    Oestreich JH; Dobesh PP
    Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the Role of Cangrelor in Patients Undergoing PCI?
    Droppa M; Geisler T
    Curr Vasc Pharmacol; 2018; 16(5):484-489. PubMed ID: 29345586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.